REGULATORY NEWS

FDA approves MelaFind detection device

Washington — The Food and Drug Administration has approved MelaFind, a melanoma detection device. Manufacturer Mela Sciences of Irvington, N.Y., plans to make the tool available starting early next year. » More

MELANOMA

Melanoma survivors at risk for future cancers

Little Rock, Ark. — Melanoma survivors — especially women — are at higher risk than the general population of developing future invasive melanomas and other cancers, a new study reports. » More

Melanoma’s economic toll: $3.5 billion annually

Atlanta — The Centers for Disease Control and Prevention estimates that at minimum, deaths caused by melanoma have a $3.5 billion negative annual impact on the nation’s economy. » More

Medi-Spa Insurance starting at $3,500/year...

Allied Health Association offers Medi – Spa Insurance starting at $3,500/yr with Low Deductible, Occurrence and Claims Made Form, Prior Acts Coverage, and Direct Patient Care Available. Uses with Botox, Brown Spot Removal, Dermal Fillers, Dermaplaning, Tattoo Removal, Laser Cellulite Treatment, Laser Skin Resurfacing, Laser Hair Removal, Thermage, Vein Treatment, Pigmented Lesion Removal, Wart Removal, velaSmooth, VelaShape, Acupuncture, Vitamin B Injections, and Chemical Peels (medium-heavy). Standard Medical Mal-Practice Coverage also available.
alliedhealth.net
Call or visit: 800-444-7546

Survey

Do you find sentinel lymph node biopsy useful in assessing prognosis of melanoma patients?

Yes | No | Yes, but only in intermediate-thickness lesions

Respond here and see what your colleagues are saying, too.

Want to see the results of our last survey regarding California’s new law banning minors from tanning beds?
Click Here.

PSORIASIS

International initiative seeks genetic keys to psoriasis

Dallas — The International Psoriasis Council has announced a collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis. » More

ROSACEA

Novel rosacea drug relieves erythema in 2B trial

Lausanne, Switzerland — Galderma Pharma has announced positive results from a phase 2b trial of a proprietary topical gel for treating patients with moderate-to-severe facial erythema due to rosacea. » More

New Job Opportunities

All Island Dermatology		Arizona Skin & Laser
Arizona Skin & Laser		Center for Dermatology Care
Cynthia Dreyer MD		Dr. Dennis Gross
David A High MD		Mark Burnett MD
MedDerm Associates		Mosaic Clinic: Dermatology
Ochsner Health System		Richard G. Glogau
Universal Dermatology

Tools

•	Information Technology
•	Meetings & Events
•	Practice Management
•	Resource Centers

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.